Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4.

Anders Elm Pedersen; S Buus; M H Claesson

doi:10.1016/j.canlet.2005.04.012

Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4.

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

We investigated the anti CT26 tumour effect of dendritic cell based vaccination with the MuLV gp70 envelope protein-derived peptides AH1 and p320-333. Vaccination lead to generation of AH1 specific cytotoxic lymphocytes (CTL) and some decrease in tumour growth of simultaneously inoculated CT26 cells. After combination with an antibody against VEGF receptor 2 (DC101), a significant increase in survival of the tumour cell recipients was observed. Also, monotherapy with an antibody against CTLA-4 (9H10), led to approximately 100% survival of tumour cell recipients. However, effective treatment of mice with already established tumours was only obtained after combination of vaccination, DC101 and 9H10 treatment in which setting 80% of the mice rejected their tumours.

Original language	English
Journal	Cancer Letters
Volume	235
Issue number	2
Pages (from-to)	229-38
Number of pages	9
ISSN	0304-3835
DOIs	https://doi.org/10.1016/j.canlet.2005.04.012
Publication status	Published - 2005

Bibliographical note

Keywords: Animals; Antigens, CD; Antigens, Differentiation; Colonic Neoplasms; Combined Modality Therapy; Dendritic Cells; Epitopes, T-Lymphocyte; Female; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; T-Lymphocytes, Cytotoxic; Vaccination; Vaccines; Vascular Endothelial Growth Factor Receptor-2

Access to Document

10.1016/j.canlet.2005.04.012

Library access?

Check availability at the Royal Danish Library

Cite this

@article{26d489e0ac0511ddb5e9000ea68e967b,

title = "Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4.",

abstract = "We investigated the anti CT26 tumour effect of dendritic cell based vaccination with the MuLV gp70 envelope protein-derived peptides AH1 and p320-333. Vaccination lead to generation of AH1 specific cytotoxic lymphocytes (CTL) and some decrease in tumour growth of simultaneously inoculated CT26 cells. After combination with an antibody against VEGF receptor 2 (DC101), a significant increase in survival of the tumour cell recipients was observed. Also, monotherapy with an antibody against CTLA-4 (9H10), led to approximately 100\% survival of tumour cell recipients. However, effective treatment of mice with already established tumours was only obtained after combination of vaccination, DC101 and 9H10 treatment in which setting 80\% of the mice rejected their tumours.",

author = "Pedersen, \{Anders Elm\} and S Buus and Claesson, \{M H\}",

note = "Keywords: Animals; Antigens, CD; Antigens, Differentiation; Colonic Neoplasms; Combined Modality Therapy; Dendritic Cells; Epitopes, T-Lymphocyte; Female; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; T-Lymphocytes, Cytotoxic; Vaccination; Vaccines; Vascular Endothelial Growth Factor Receptor-2",

year = "2005",

doi = "10.1016/j.canlet.2005.04.012",

language = "English",

volume = "235",

pages = "229--38",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4.

AU - Pedersen, Anders Elm

AU - Buus, S

AU - Claesson, M H

N1 - Keywords: Animals; Antigens, CD; Antigens, Differentiation; Colonic Neoplasms; Combined Modality Therapy; Dendritic Cells; Epitopes, T-Lymphocyte; Female; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; T-Lymphocytes, Cytotoxic; Vaccination; Vaccines; Vascular Endothelial Growth Factor Receptor-2

PY - 2005

Y1 - 2005

N2 - We investigated the anti CT26 tumour effect of dendritic cell based vaccination with the MuLV gp70 envelope protein-derived peptides AH1 and p320-333. Vaccination lead to generation of AH1 specific cytotoxic lymphocytes (CTL) and some decrease in tumour growth of simultaneously inoculated CT26 cells. After combination with an antibody against VEGF receptor 2 (DC101), a significant increase in survival of the tumour cell recipients was observed. Also, monotherapy with an antibody against CTLA-4 (9H10), led to approximately 100% survival of tumour cell recipients. However, effective treatment of mice with already established tumours was only obtained after combination of vaccination, DC101 and 9H10 treatment in which setting 80% of the mice rejected their tumours.

AB - We investigated the anti CT26 tumour effect of dendritic cell based vaccination with the MuLV gp70 envelope protein-derived peptides AH1 and p320-333. Vaccination lead to generation of AH1 specific cytotoxic lymphocytes (CTL) and some decrease in tumour growth of simultaneously inoculated CT26 cells. After combination with an antibody against VEGF receptor 2 (DC101), a significant increase in survival of the tumour cell recipients was observed. Also, monotherapy with an antibody against CTLA-4 (9H10), led to approximately 100% survival of tumour cell recipients. However, effective treatment of mice with already established tumours was only obtained after combination of vaccination, DC101 and 9H10 treatment in which setting 80% of the mice rejected their tumours.

U2 - 10.1016/j.canlet.2005.04.012

DO - 10.1016/j.canlet.2005.04.012

M3 - Journal article

C2 - 15927356

SN - 0304-3835

VL - 235

SP - 229

EP - 238

JO - Cancer Letters

JF - Cancer Letters

IS - 2

ER -